LMNX - Luminex seeks FDA approval for joint SARS-CoV-2 and Flu/RSV assay

Luminex Corporation (LMNX) has applied for an Emergency Use Authorization from the FDA for a multi-analyte respiratory panel that combines Flu A/B and respiratory syncytial virus (“RSV”) targets with the SARS-CoV-2 target.The company says that the filing marks a key milestone in a funding award it received from the Biomedical Advanced Research and Development Authority (“BARDA”), which has supported the development and validation of the assay."We are grateful to BARDA for supporting development of this important new assay, and are pleased to have fulfilled our commitment to file for EUA so quickly," commented Nachum "Homi" Shamir, CEO of Luminex.Last week, Luminex announced the Emergency Use Authorization it received from the FDA for a new expanded version of its NxTAG Respiratory Pathogen Panel.

For further details see:

Luminex seeks FDA approval for joint SARS-CoV-2 and Flu/RSV assay